Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of MGNX is 3.6 and suggests 98% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell